In recent years, GLP-1 receptor agonists such as Ozempic, Mounjaro, and Wegovy have surged in popularity, first gaining approval for the treatment of type 2 diabetes by helping regulate blood sugar levels and improve insulin sensitivity. However, researchers and physicians soon discovered an additional effect: these medications substantially suppress appetite and promote weight loss. This led to a dramatic increase in off-label use by individuals seeking to shed pounds, creating a cultural and medical phenomenon in which the drugs became synonymous with rapid and often visible weight reduction. Their popularity has been fueled by widespread societal pressures regarding body image, rising obesity rates, and the allure of pharmaceutical solutions that promise results more quickly than lifestyle changes alone.

While these medications are undeniably effective in controlled studies and under medical supervision, questions have emerged regarding the long-term implications of their widespread use. The relative novelty of GLP-1 drugs means that the long-term systemic effects are still poorly understood, raising concerns about cumulative metabolic disruptions, pancreatic stress, and unintended consequences that may only manifest years into regular usage. Furthermore, the increasing commodification and social visibility of these medications—driven by social media, celebrity endorsements, and public discourse.